(Q40861679)

24 September 2017

title

Tacrine interacts with different sites on nicotinic receptor subtypes in SH-SY5Y neuroblastoma and M10 cells (English)

1 reference

24 September 2017

1 reference

Svensson AL

1 reference

24 September 2017

language of work or name

English

0 references

publication date

1 August 2000

1 reference

Behavioural Brain Research

24 September 2017

published in

1 reference

24 September 2017

volume

113

1 reference

24 September 2017

issue

1-2

1 reference

24 September 2017

page(s)

193-197

1 reference

Chronic ethanol treatment decreases [3H]epibatidine and [3H]nicotine binding and differentially regulates mRNA levels of nicotinic acetylcholine receptor subunits expressed in M10 and SH-SY5Y neuroblastoma cells.

24 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0166-4328%2800%2900213-8

7 January 2021

Nicotinic receptor stimulation protects neurons against beta-amyloid toxicity.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-4328%2800%2900213-8

7 January 2021

A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-4328%2800%2900213-8

7 January 2021

Nicotinic acetylcholine receptors in health and disease

1 reference

https://api.crossref.org/works/10.1016%2FS0166-4328%2800%2900213-8

7 January 2021

Characterization of Nicotinic Acetylcholine Receptors Expressed by Cells of the SH-SY5Y Human Neuroblastoma Clonal Line

1 reference

https://api.crossref.org/works/10.1016%2FS0166-4328%2800%2900213-8

7 January 2021

Allosteric modulation of Torpedo nicotinic acetylcholine receptor ion channel activity by noncompetitive agonists

1 reference

https://api.crossref.org/works/10.1016%2FS0166-4328%2800%2900213-8

7 January 2021

Efficacy of tacrine and lecithin in mild to moderate Alzheimer's disease: double blind trial

1 reference

https://api.crossref.org/works/10.1016%2FS0166-4328%2800%2900213-8

7 January 2021

Nicotinic system involvement in Alzheimer's and Parkinson's diseases. Implications for therapeutics.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-4328%2800%2900213-8

7 January 2021

Long-term tacrine treatment in three mild Alzheimer patients: effects on nicotinic receptors, cerebral blood flow, glucose metabolism, EEG, and cognitive abilities.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-4328%2800%2900213-8

7 January 2021

Imaging of nicotinic and muscarinic receptors in Alzheimer's disease: effect of tacrine treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0166-4328%2800%2900213-8

7 January 2021

Chronic nicotine treatment up-regulates alpha3 and alpha7 acetylcholine receptor subtypes expressed by the human neuroblastoma cell line SH-SY5Y.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-4328%2800%2900213-8

7 January 2021

Tacrine interacts with an allosteric activator site on alpha 4 beta 2 nAChRs in M10 cells

1 reference

https://api.crossref.org/works/10.1016%2FS0166-4328%2800%2900213-8

7 January 2021

Tacrine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0166-4328%2800%2900213-8

7 January 2021

Regulation of nicotinic receptor subtypes following chronic nicotinic agonist exposure in M10 and SH-SY5Y neuroblastoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS0166-4328%2800%2900213-8

7 January 2021

Nicotine modulates the neurotoxic effect of beta-amyloid protein(25-35)) in hippocampal cultures

1 reference

https://api.crossref.org/works/10.1016%2FS0166-4328%2800%2900213-8

7 January 2021

10.1016/S0166-4328(00)00213-8

Identifiers

DOI

1 reference

24 September 2017

1 reference